
KYTX Stock Forecast & Price Target
KYTX Analyst Ratings
Bulls say
Kyverna Therapeutics is a promising clinical-stage biopharmaceutical company with a focused approach on developing cell therapies for autoimmune diseases. The company's recent positive results from the Phase 1 COMPARE study add to the potential upside for its lead product, KYV-101, in treating refractory rheumatoid arthritis (RA). With strong clinical and translational data, a positive regulatory outlook, and an estimated $800M in peak sales, Kyverna's future as a leader in the growing I&ICAR-T market looks bright.
Bears say
Kyverna Therapeutics is facing potential competition in the autoimmune disease market with an allogeneic therapy containing the same CAR as its current product, KYV-101. Additionally, the cost burden of $0.7M-$1.5M per patient and low success rate of its manufacturing support a negative outlook on the company's financials and margins. The company may struggle to maintain profitability and sustain long-term success in the market.
This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KYTX Analyst Forecast & Price Prediction
Start investing in KYTX
Order type
Buy in
Order amount
Est. shares
0 shares